|
Market Closed -
Nasdaq
21:00:00 08/09/2026 BST
|
Pre-market 11:49:26 | |||
| 140.33 USD | -3.59% |
|
139.40 | -0.66% |
| 09-04 | Is the party already over for AI-boosted momentum kings? |  |
| 09-03 | Evercore ISI Adjusts Moderna Price Target to $80 From $50, Maintains In Line Rating | MT |
| Market Cap | 56.02B 48.17B 45.32B 41.36B 77.18B 5,311B 77.58B 537B 208B 2,715B 210B 206B 8,639B | P/E 2026 * |
-16.7x | P/E 2027 * | -28.5x |
|---|---|---|---|---|---|
| Enterprise Value | 52.37B 45.03B 42.36B 38.66B 72.15B 4,965B 72.52B 502B 194B 2,538B 197B 192B 8,076B | EV / Sales 2026 * |
24.9x | EV / Sales 2027 * | 22.1x |
| Free-Float |
92.68% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| MRNA | Delayed | |
CBOE
| MRNA | Real-time | |
|
Borsa Italiana
| 1MRNA | End-of-day quote | |
|
Mexican S.E.
| MRNA * | End-of-day quote | |
|
Xetra
| 0QF | Delayed | |
|
Tradegate
| 0QF | Real-time | |
|
Wiener Boerse
| MRNA | End-of-day quote | |
|
Kazakhstan S.E.
| MRNA_KZ | End-of-day quote | |
|
London S.E.
| 0A45 | Delayed | |
|
CBOE
| Real-time | ||
|
Boerse Muenchen
| 0QF | Real-time | |
|
CBOE
| 0A45 | Real-time | |
|
Deutsche Boerse AG
| 0QF | Delayed | |
|
Börse Stuttgart
| 0QF | Delayed | |
|
Lima
| MRNAUS | End-of-day quote | |
|
Swiss Exchange
| MRNA | Delayed | |
|
Swiss Exchange
| MRNA | Delayed |
Last Transcript : Moderna, Inc.
| 1 day | -3.59% | ||
| 1 week | -9.04% | ||
| Current month | -0.01% | ||
| 1 month | +137.16% | ||
| 3 months | +194.81% | ||
| 6 months | +167.19% | ||
| Current year | +375.86% |
| 1 week | 139.7 |  | 154.69 |
| 1 month | 58.41 | | 176.66 |
| Current year | 29.81 | | 176.66 |
| 1 year | 22.28 | | 176.66 |
| 3 years | 22.28 | | 176.66 |
| 5 years | 22.28 | | 464.85 |
| 10 years | 11.54 | | 497.49 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 54 | 28/02/2011 |
James Mock
DFI | Director of Finance/CFO | 49 | 05/09/2022 |
Stephen Hoge
PSD | President | 50 | 31/10/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Noubar Afeyan
CHM | Chairman | 63 | 31/01/2012 |
Stéphane Bancel
BRD | Director/Board Member | 54 | 28/02/2011 |
Francois Nader
BRD | Director/Board Member | 69 | 10/12/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 01/09/26 | Exercice | General Counsel | 15,793 | 0.0040% | ||
| 01/09/26 | Exercice | Chief Financial Officer | 6,147 | 0.0015% | ||
| 01/09/26 | Exercice | Chairperson | 23,055 | 0.0058% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.59% | -9.04% | +465.16% | +30.37% | 56.02B | |
| -2.10% | -1.64% | +45.10% | -2.45% | 80.91B | |
| -0.78% | -1.52% | -18.45% | -36.25% | 60.46B | |
| -1.77% | -5.26% | -9.16% | +29.36% | 49.63B | |
| -1.55% | -7.62% | -2.58% | +147.15% | 45.88B | |
| -3.77% | -1.64% | +50.34% | -17.95% | 31.4B | |
| -1.85% | -0.49% | +43.72% | +94.44% | 25.22B | |
| -2.00% | -3.54% | -2.68% | +156.40% | 22.25B | |
| -1.44% | -0.97% | +62.91% | +103.16% | 16.59B | |
| -3.15% | -7.97% | -24.67% | +719.34% | 14.38B | |
| Average | -2.20% | -2.11% | +60.97% | +122.36% | 40.27B | |
| Weighted average by Cap. | -2.13% | -1.64% | +77.80% | +61.75% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.1B 1.81B 1.7B 1.55B 2.89B 199B 2.91B 20.14B 7.79B 102B 7.89B 7.72B 324B | 2.44B 2.1B 1.97B 1.8B 3.36B 231B 3.38B 23.36B 9.04B 118B 9.15B 8.95B 376B |
| Net income | -3.31B -2.85B -2.68B -2.45B -4.56B -314B -4.59B -31.75B -12.28B -161B -12.44B -12.17B -511B | -1.94B -1.67B -1.57B -1.44B -2.68B -184B -2.69B -18.64B -7.21B -94.24B -7.3B -7.14B -300B |
| Net Debt | -3.65B -3.14B -2.95B -2.7B -5.03B -346B -5.06B -35.01B -13.54B -177B -13.72B -13.42B -563B | -2.17B -1.87B -1.75B -1.6B -2.99B -206B -3B -20.79B -8.04B -105B -8.15B -7.97B -334B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/09/26 | US$140.33 | -3.59% | 10,308,621 |
| 04/09/26 | US$145.55 | -2.23% | 14,966,547 |
| 03/09/26 | US$148.87 | -1.29% | 13,290,379 |
| 02/09/26 | US$150.81 | -2.24% | 16,563,188 |
| 01/09/26 | US$154.27 | +9.93% | 25,831,743 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MRNA Stock
Select your edition
All financial news and data tailored to specific country editions
